FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783100115> ?p ?o ?g. }

• W2783100115 endingPage "4481" @default.
• W2783100115 startingPage "4481" @default.
• W2783100115 abstract "Abstract Background: Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Treatment relies upon corticosteroids and immunosuppressive agents with limited efficacy and considerable side-effects. Evolving research points to the complex involvement of immune T, B, and myeloid cells in the pathogenesis of cGVHD. Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK) which inhibits the activation of B-cells, specific T-cell subsets, and certain myeloid cells that are implicated in cGVHD. Substantial clinical benefit was demonstrated in an open-label phase 1b/2 study of ibrutinib in patients with cGVHD that had failed frontline therapy (Miklos et al ASH 2016). Based upon this data, ibrutinib is indicated by the US FDA for the treatment of adult patients with cGVHD after failure of one or more lines of systemic therapy. Methods: Blood samples were collected before and multiple timepoints after starting ibrutinib 420mg daily therapy from 42 subjects with cGVHD that had failed frontline therapy (Miklos et al ASH 2016). Correlative analyses included Nanostring gene expression profiling, Luminex and ELISA based plasma testing, CyTOF phospho-immunophenotyping, and ex-vivo T-cell stimulation assays. Results: Initial data from 8 patients using targeted, Nanostring gene expression analysis showed ibrutinib reduced inflammatory genes including NFkB-1 and chemokines CXCL10, CCL7 and CCL3 (2.6, 2.3, 25, and 1.8-fold decrease over first 3 months, respectively). Luminex plasma quantification supported gene expression profiling results, and unveiled several additional chemotactic, inflammatory, and fibrotic factors which were down modulated by ibrutinib therapy including CCL22, CXCL9, CXCL10, IL-8, sCD25, CCL4, and ST2 (69-80% of patients showed decreasing trend). 42-parameter CyTOF single cell analysis revealed a 10-fold reduction in absolute numbers of cGVHD implicated pre-germinal center B-cells (CD19+, CD27+, CD38+, IgD+), and notably diminished Tfh, Th17, and total B cells (2.6, 1.5, and 1.4-fold decrease over first 90 days, respectively) following ibrutinib therapy. Relative numbers of CD4 and CD8 T-cells, class-switched B-cells, and CD14+ monocytes remained unchanged, and iNKT, Th1, and Treg cells increased incrementally (1.8, 1.2, and 1.1-fold at day 90, respectively). IgG plasma levels persisted while IgM significantly decreased corroborating an ibrutinib germinal center effect that did not deplete long-lived plasma cells. Furthermore, T cell reactivity against influenza increased, and antibodies against EBV and tetanus remained unchanged. Strikingly, single cell phosphorylation analysis showed BTK and ITK signaling was attenuated following ibrutinib treatment in defined B and T cell subsets (Figure 1). Specifically, PLCγ1/2 activation was simultaneously diminished in the pre-germinal center and plasmablast B-cell subsets. Conclusions: Our examination of the biologic and cellular mechanisms which support the clinical results of ibrutinib in the setting of cGVHD demonstrate that ibrutinib selectively inhibits cGVHD pathogenic pre-germinal center B-cells and Tfh cells, while preserving immune memory and Th1 T-cells. These data are especially salient given the clinical efficacy of ibrutinib in cGVHD, and the meticulous nature of the correlative studies designed to elucidate the multifactorial mechanism of action in this life-threatening disease. Download : Download high-res image (385KB) Download : Download full-size image Disclosures Sahaf: Pharmacyclics: Research Funding; Stanford: Patents & Royalties. Tebaykin: Stanford University: Patents & Royalties. Hopper: Pharmacyclics: Employment. Cheung: Pharmacyclics: Employment; AbbVie: Equity Ownership. Bittencourt: Pharmacyclics: Employment, Research Funding; AbbVie: Equity Ownership, Research Funding. Cutler: Astellas: Consultancy; Incyte: Consultancy; Bristol-Myers Squibb: Consultancy; Kite: Consultancy; Pharmacyclics: Consultancy; Pfizer: Consultancy. Arora: Takeda Oncology: Consultancy. Waller: Cambium Medical Technologies: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Cerus: Equity Ownership; Helocyte: Consultancy; National Institutes of Health: Research Funding; Katz Foundation: Research Funding; AMGEN: Consultancy; PRA: Consultancy; Coulter Foundation: Research Funding; Celldex: Consultancy; Chimerix: Equity Ownership; Novartis Pharmaceuticals Corporation: Consultancy, Honoraria, Research Funding. Jagasia: Janssen: Consultancy, Research Funding; Mallinckrodt: Consultancy; Therakos: Consultancy, Research Funding. Flowers: Pharmacyclics: Consultancy. Logan: Novartis: Consultancy, Research Funding; Incyte: Consultancy; Kite: Research Funding; Astellas: Research Funding; Jazz: Consultancy; Amgen: Consultancy; Pharmacyclics: Research Funding; Shire: Consultancy. Jaglowski: Pharmacyclics: Consultancy, Research Funding. Lih: AbbVie: Equity Ownership; Pharmacyclics: Employment. Solman: Pharmacyclics LLC, an AbbVie Company: Employment, Other: Travel, Accommodations, Expenses; AbbVie: Equity Ownership. Lal: Gilead Sciences: Employment; AbbVie: Equity Ownership; The Permanente Medical Group (TPMG): Employment; Pharmacyclics LLC, an AbbVie Company: Employment. Styles: Pharmacyclics LLC, an AbbVie Company: Employment; AbbVie: Equity Ownership. Hill: Amgen: Employment, Equity Ownership, Patents & Royalties; Pharmacyclics: Employment; AbbVie: Equity Ownership; Miravant Medical: Patents & Royalties. James: AbbVie: Equity Ownership; Pharmacyclics LLC, an AbbVie Company: Employment. Bendall: Fluidigm Sciences: Consultancy, Other: Travel, Accomodations, Expenses; Bluebird Bio: Other: Travel, Accomodations, Expenses, Research Funding; Ionpath, Inc.: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Boehringer-ingelheim: Consultancy, Other: Travel, Accomodations, Expenses; Pharmacyclics: Research Funding. Dubovsky: Pharmacyclics LLC, an AbbVie Company: Employment; AbbVie: Equity Ownership." @default.
• W2783100115 created "2018-01-26" @default.
• W2783100115 creator A5001483654 @default.
• W2783100115 creator A5001854837 @default.
• W2783100115 creator A5004256884 @default.
• W2783100115 creator A5011386306 @default.
• W2783100115 creator A5016644532 @default.
• W2783100115 creator A5029278364 @default.
• W2783100115 creator A5029457767 @default.
• W2783100115 creator A5041735776 @default.
• W2783100115 creator A5045383208 @default.
• W2783100115 creator A5054714265 @default.
• W2783100115 creator A5056221732 @default.
• W2783100115 creator A5056327118 @default.
• W2783100115 creator A5062041233 @default.
• W2783100115 creator A5062975737 @default.
• W2783100115 creator A5064062205 @default.
• W2783100115 creator A5067818268 @default.
• W2783100115 creator A5070008988 @default.
• W2783100115 creator A5071733656 @default.
• W2783100115 creator A5072835425 @default.
• W2783100115 creator A5081161234 @default.
• W2783100115 creator A5081926380 @default.
• W2783100115 creator A5086922431 @default.
• W2783100115 date "2017-12-07" @default.
• W2783100115 modified "2023-09-27" @default.
• W2783100115 title "Ibrutinib Inhibits cGVHD Pathogenic Pre-Germinal Center B-Cells and Follicular Helper Cells While Preserving Immune Memory and Th1 T-Cells" @default.
• W2783100115 doi "https://doi.org/10.1182/blood.v130.suppl_1.4481.4481" @default.
• W2783100115 hasPublicationYear "2017" @default.
• W2783100115 type Work @default.
• W2783100115 sameAs 2783100115 @default.
• W2783100115 citedByCount "1" @default.
• W2783100115 countsByYear W27831001152019 @default.
• W2783100115 crossrefType "journal-article" @default.
• W2783100115 hasAuthorship W2783100115A5001483654 @default.
• W2783100115 hasAuthorship W2783100115A5001854837 @default.
• W2783100115 hasAuthorship W2783100115A5004256884 @default.
• W2783100115 hasAuthorship W2783100115A5011386306 @default.
• W2783100115 hasAuthorship W2783100115A5016644532 @default.
• W2783100115 hasAuthorship W2783100115A5029278364 @default.
• W2783100115 hasAuthorship W2783100115A5029457767 @default.
• W2783100115 hasAuthorship W2783100115A5041735776 @default.
• W2783100115 hasAuthorship W2783100115A5045383208 @default.
• W2783100115 hasAuthorship W2783100115A5054714265 @default.
• W2783100115 hasAuthorship W2783100115A5056221732 @default.
• W2783100115 hasAuthorship W2783100115A5056327118 @default.
• W2783100115 hasAuthorship W2783100115A5062041233 @default.
• W2783100115 hasAuthorship W2783100115A5062975737 @default.
• W2783100115 hasAuthorship W2783100115A5064062205 @default.
• W2783100115 hasAuthorship W2783100115A5067818268 @default.
• W2783100115 hasAuthorship W2783100115A5070008988 @default.
• W2783100115 hasAuthorship W2783100115A5071733656 @default.
• W2783100115 hasAuthorship W2783100115A5072835425 @default.
• W2783100115 hasAuthorship W2783100115A5081161234 @default.
• W2783100115 hasAuthorship W2783100115A5081926380 @default.
• W2783100115 hasAuthorship W2783100115A5086922431 @default.
• W2783100115 hasConcept C126322002 @default.
• W2783100115 hasConcept C13373296 @default.
• W2783100115 hasConcept C159654299 @default.
• W2783100115 hasConcept C170493617 @default.
• W2783100115 hasConcept C203014093 @default.
• W2783100115 hasConcept C2777408962 @default.
• W2783100115 hasConcept C2777938653 @default.
• W2783100115 hasConcept C2778453870 @default.
• W2783100115 hasConcept C2778461978 @default.
• W2783100115 hasConcept C2779878957 @default.
• W2783100115 hasConcept C2911091166 @default.
• W2783100115 hasConcept C42362537 @default.
• W2783100115 hasConcept C502942594 @default.
• W2783100115 hasConcept C71924100 @default.
• W2783100115 hasConcept C8891405 @default.
• W2783100115 hasConcept C90059517 @default.
• W2783100115 hasConcept C96926380 @default.
• W2783100115 hasConceptScore W2783100115C126322002 @default.
• W2783100115 hasConceptScore W2783100115C13373296 @default.
• W2783100115 hasConceptScore W2783100115C159654299 @default.
• W2783100115 hasConceptScore W2783100115C170493617 @default.
• W2783100115 hasConceptScore W2783100115C203014093 @default.
• W2783100115 hasConceptScore W2783100115C2777408962 @default.
• W2783100115 hasConceptScore W2783100115C2777938653 @default.
• W2783100115 hasConceptScore W2783100115C2778453870 @default.
• W2783100115 hasConceptScore W2783100115C2778461978 @default.
• W2783100115 hasConceptScore W2783100115C2779878957 @default.
• W2783100115 hasConceptScore W2783100115C2911091166 @default.
• W2783100115 hasConceptScore W2783100115C42362537 @default.
• W2783100115 hasConceptScore W2783100115C502942594 @default.
• W2783100115 hasConceptScore W2783100115C71924100 @default.
• W2783100115 hasConceptScore W2783100115C8891405 @default.
• W2783100115 hasConceptScore W2783100115C90059517 @default.
• W2783100115 hasConceptScore W2783100115C96926380 @default.
• W2783100115 hasLocation W27831001151 @default.
• W2783100115 hasOpenAccess W2783100115 @default.
• W2783100115 hasPrimaryLocation W27831001151 @default.
• W2783100115 hasRelatedWork W2588885669 @default.
• W2783100115 hasRelatedWork W2908473823 @default.
• W2783100115 hasRelatedWork W2919004412 @default.
• W2783100115 hasRelatedWork W2979397746 @default.
• W2783100115 hasRelatedWork W2982831586 @default.

• next